Reference field note
Retatrutide
A reference record with its source links, an editorial reading note, and questions to carry forward.
Aliases: LY3437943
- Status
- Investigational
- Evidence label
- Randomized evidence
- Index topics
- Metabolism
- Status as of
The record
Recorded fields
- Mechanism
- Activates GIP, GLP-1 and glucagon receptors.
- Evidence
- A randomized obesity trial was funded by Lilly.
- Limitations
- Trial averages do not predict an individual outcome.
- Safety
- The trial reported gastrointestinal adverse events.
- Route context
- Studied as a subcutaneous injection.
- Approval scope
- Investigational; no FDA-approved product.
Pause and consider
A reading note
A useful response may address a narrower question than the one you brought. Rather than accepting or dismissing the whole response, name the part it addresses and keep that part intact. Write the remaining request beside it in different words. This creates a clear handoff: here is what the response helps establish, and here is what I still want to understand. The remaining request might call for another explanation or a different comparison. Treating a partial answer carefully preserves its contribution while preventing it from quietly taking the place of a broader answer.
Questions to carry forward
- Which part of my original question does this response address directly?
- How can I describe the remaining request without repeating what has already been addressed?
- Would the next response need to extend this explanation or answer a different question?
Follow the record
References
- FDA GLP-1
FDA · Checked
- Jastreboff
PubMed · Checked
Prepared by the Panda Bear editorial team. Educational information; no independent medical review is claimed.